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group (fig 3, left), largely because penicillin prevented 
Ieptospiruria (fig 3, right); after the start of treatment (or 
placebo) leptospires were isolated from 58% of placebo 
group patients but from only 13% of those in the treatment 
group (p < 0'01). 
Discussion 
This study clearly shows that intravenous penicillin 
benefits patients with severe leptospirosis, even when given 
late in the course of illness. 76% of the study patients had 
either renal or hepatic dysfunction, usually both, and only 1 
patient had had symptoms for less than 5 days before 
treatment, yet every measurable aspect of disease improved 
with penicillin. Some animal studies have shown that 
penicillin exerts a beneficial effect only when given soon 
after infection, before jaundice appears" 12 but others have 
given different results. There were fewer deaths, and the 
course of the disease was less severe, among penicillin-
treated jaundiced puppies than among untreated controls. U 
Leptospiraemia and leptospiruria were eradicated in the 
treated dogs. Hamsters severely ill with leptmlpirosis 
survived when given penicillin G'4 or the newer penicillins' 
I to 2 days before expcrted time of death. The many 
previous evaluations of penicillin in the treatment of human 
leptospirosis have also given conflicting results, but only 
four of these studies included concurrent controls; two 
showed no beneficial effect, U.,6 another slight benefit,17 and 
the fourth considerable benefit. 'R However, these studies 
were neither double-blind nor adequately randomised, and 
penicillin was given in lower doses than that used by us and it 
was not given intravenously. 
The beneficial effects of penicillin on affected kidneys 
have particular clinical relevance. Creatinine rises lasted 
only a third as long in the treatment group (fig 2) and 
leptospiruria diminished with penicillin (fig 3). These 
findings suggest that it is by eradicating \eptospires that 
penicillin curtails the duration of renal dysfunction and thus 
shortens the period of susceptibility to complete renal failure 
and death. 
Oral doxycycline has been shown to be beneficiaP but its 
value in severe disease or when given after day 2 has not been 
established.' In addition, antibiotics must be given 
parenterally to patients with 5e"\'ere leptospirosis, many of 
whom are vomiting.4•1' Parenteral doxycycline is expensive 
and al!;() not available in many countries, including the 
Philippines.20 For these reasons it was not chosen for our 
study. The beneficial effects of doxycycline in mild cases, 
although statistically significant, were !:mall. Symptoms and 
fever were reduced by only 2 days. J Our randomised, 
placebo-controlled, well-controlled trial has shown that 
intravenous pencillin produced striking results in precisely 
those individuals in whom optimum therapy is most 
important-patients with serious, potentially fatal disease-
even when therapy started late in the course of disease. 
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Summary A child \\;th homozygous protein C 
deficiency was treated at age 20 months by 
orthotopic hepatic transplantation.' Postoperatively there 
was complete reconstitution of protein C activity and 
resolution of the thrombotic condition. 
Introduction 
PROTEIN C is a vitamin-K-dependent anticoagulant 
glycoprotein which, once activated by thrombin, inhibits 
activated factors V and vln and stimulates fibrinolysis.' 
Current evidence suggests that protein C deficiency is 
inherited as an autosomal codominant trait.24 Patients 
heterozygous for protein C deficiency usually have about 
50% of normal protein Cactivity. An increased incidence of 
serious thrombosis has been reported amongst the 
heterozygous relatives of several kindreds. L< 8 Patients with 
homozygous protein C deficiency typically present shortly 
after birth with purpura fulminans, retinal haemorrhage, 
and evidence of central nervous system or renal throm-
bosisK~y1 Protein C activity levels have been undetectable in 
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factor X levels (tJ.) b<!fore (time 0) and after hepatic transplantlltlcn. 
all reported cases, and the disease is invariably fatal if left 
Wltreated. 
Although fresh frozen plasma (FFP), coumarin 
anticoagulants, and factor IX concentrates have been used 
successfully in the treatment of homozygous protein C 
deficiency, all existing treatments have substantial 
drawbacks. The biological half-life of injected protein C 
( < 8 h) necessitates unacceptably frequent administration of 
plasma products, and poor access to veins is often another 
limiting factor. The thrombotic tendency can be controlled 
with cownarin anticoagulants, but only in doses that 
severely restrict normal childhood activities and CIIITY a risk 
of fatal haemorrhage. . 
Several lines of evidence suggest that the liver is the major 
site of protein C synthesis. First, other vitamin-K-
dependent factors (II, VII, IX, and X) are synthesised in the 
liver; second, protein C levels are reduced in liver disease;tW 
third, synthesis of soluble protein C by a hmnan hepatoma 
line has been demonstrated in vitro;t9 and, fourth, eDNA 
inserts in a grll library prepared from hwnan liver mRNA 
have been shown to code for protein C.:IO These observations 
led us to attempt orthotopic hepatic transplantation as 
primary therapy for a patient with protein C deficiency. 
Case-report and Methods 
The patient, bom at full term, WM the child of first rousins. 
Details of his clinical course and of protein C Icvels in the pedi~ 
gree have been presented dscwhere." Retinal and vitreous 
haemorrhages (ultimately resulting in complete blindness') were 
noted shortly after birth. Purpuric skin Inions were tint observed at 
24 h of age. Protein C antigen was present at 17 D/. of normal levels, 
but protein C activity was undetectable. Therapy with FFP WM 
instituted at 48 h of age, and waK~ continued until 8! months of age. 
Two attempts at withdrawal of FFP were tIS!Ociated with renal 
failure, microangiopathic haemolytic anaemia, lind fibrinolysis. At 
age 81 months, warfarin ('Coumadin') therapy was auccessfully 
instituted during phased withdrawal ofFFP. At age 15 months an 
intracranial hacmatoma developed after a fall from bed. Warfarin 
was discontinued and treatment with FFP was reinstituted for six 
weeks. Warfarin was then reswned, IIIld the haelnatoma raolved 
without neurological sequelae. . 
At age 20 months, the patient was transferred ID the Oilldren's 
Hospital of Pittsburgh for orthotopic hepatic transplantation. 
Before surgery, he had been receiving warfarin 0·5 rng/kg per 
day-3·0 mg in the morning and 2·5 mg at night. The last dose (2'5 
mg) was administered 6 h before induction of anesthesia. At the 
time of induction the prothrombin and partial thromboplastin times 
were 25·6 s (control 11·8) and 57·2 s (oontrol 25), respectively. 
5 mg vitamin K, was given intramuscularly, followed by an 
intravenous infusion of 10 ml/kg FFP. The prouin ~ antisen and 
THE LANCET, FEBRUARY '1:1, 1988 
. ',I .:' 
Ll!VELS OF ADDITIONAL OOAGULATION FACTORS I'tlEOPBRATIVBL Y 
AND POSTOPERA T1VBL y* 
Factor . Protein 
Time II V VII VIII IX X XI XII S 
Day I (preop) 029 0·76 0·33 270 0·39 023 EF~ 0·96 I 
Day I (postop) 009 0·13 0·07 0'65 0·02 0'10 (}{l3 0·36 
Day 2 0·\3 0·27 O-OS 1·20 0·31 0·12 (){)7 0·15 <0·12 
Day 3 031 036 029 DO 061 020 ()-18 0·13 0·64 
Day 4 0·37 0·46 0'32 1·60 0·78 0·31 ()-27 0·\3 
Day 5 056 074 0·42 2·25 HO 054 (}..f2 0·32 1·37 
Day 6 0·54 I{l() 0·58 2-55 1'10 0·64 1)55 0·47 '·66 Day 8 0·54 080 0·64 2·75 1·05 0·68 ()-72 0·69 1·37 
Day 10 1·60 1·50 0·60 3-70 1·50 0·90 ()-96 1-05 
·AII assays are functlona1, with nonna! Vlllues of 50-150"1., expressed as 
unin/m!. ' . . 
activity levels immediately after the infusion were 29% and 24%, 
respectively. Maximwn reduction of the prothrombin time was 
achieved 41 h after induction, at which time the prothrombin time 
was 14·8 5 with a partial thromboplastin time of 31·6 s .. 
Revascularisation of the graft was complicated by hepatic artery and 
portal vein thrombo!lis. Heparin, 3 mg/kg as a single intravenous 
bolus, was administered immediately before thrombectomy of both 
. vessels; however, thrombectomy of the poMlll vein failed, 
necessitating placement of a vein graft from the oonfluence of the 
splenic and superior mesenteric arteries to the hilum of me liver. A 
Roux-en-Y cholcdocho;e;unostomy was performed. 
. Postoperatively, the patient was maintained on aspirin 40 mg/kg 
once daily, dipyridamole I mglkg orally twice daily, tapering doses 
of prednisone, and cyclosporin adjusted to maintain serum levels of 
. approximately 5()() nglml as measured by radioinunWlOllllSBY. 
Protein C levels improved steadily after reaching a nadir 24 h 
postoperatively (figure). In the second week after transplantation an 
episode of preswned rejection characterised by lymphocytic 
infiltration of the hepatic parenchyma and portal areas and mild 
increases in serum transaminases WM treated with OKT3 
monoclonal antibody. The liver enzymes fell, but four weeks after 
transplantation the patient became feverish and irritable, with 
atypicsllymphocytosis and recurrent modest rises in transaminases. 
A cerebrospinal nuid mononuclear cell pleocytosis reached a 
maximwn of 247//11 six weeks after transplantation; this remained ) 
unexplained and the patient improved spontanecusly. He has been 
treated subsequently for two episodes of pneumoroccal septicaemia 
without meningitis, the second within three weeks of administration 
of pneumococcal vaccine ePnu-immune'). He remains symptom-
free with regard to his initial coagulation disorder. Protein C levels 7 
months after hepatic transplantation are nonna!. 
Laboratory Methods 
Coagulation facton were assayed by published methods.21 -2.'1 
Protein C functional assay was done by the method ofBenina' and 
of o>mp et sP' (reagents from American Diagnostics Inc, 
Greenwich, Cr). A venom derivative, 'Protac CO, converts hwnan 
protein C to the active protease (aPC) which is then measured on a 
chromogenic substrate, ·Spectrozyme-aPC'. Protein C 
immunological assay was done by the rocket technique in prepared 
plates from Helena Laboratories (Beaumont, TX). For both kinetic 
and immunological assays, the nonnal ranges were 65-145% of 
laboratory normal standard. Protein S immunological assay WM 
likewise done with the rocket technique, antibody being purchased 
from American Diagnostica. The nonnal range was 50-150% of 
laboratory nonna! ltandard. The C4 bound protein was 
precipitated with polyethylene glycol at 3·'75%. Crossed 
inununoelectrophoresir" WM used if the result with rocket assay 
. was low. . . . 
Results 
The accompanying figure shows post-transplantation 
levels of factor X and functional and antigenic protein C, and 
the table gives results of additional coagulation a!SBys. The 
time-course and pattern of protein C recovery did not differ 
noticeably from that of other vitamin-K -dependent 
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procoagubnt factors. There were no thrombotic 
compliauions in the postoperative period. 
Discussion 
The sua:essful reconstitution of protein C activity in this 
patient establishes hepatic transplantation as a useful 
treatmem for an otherwise catastrophic illness. The n:sults 
also unequivocally confirm that the liver is a majof site of 
protein C synthesis. Preoperatively, there was cause for 
concern DOt only about the ability of the transplanted liver to 
synthesise protein C but also about the pattern of 
reconstirurion. If protein C had been synthesised more 
slowly than the procoagulant proteins, for example, then an 
imbalance between procoagulant and anticoagulant 
activities might have led to postoperative thromboses. A 
similar imbalance may account for the episodes of skin 
necrosis that occur in heterozygotes for protein C deficiency 
who arc: recelvmg warfarinK~SKKlT The explanation, 
presumably, is that protein C concentrations fall quickly 
after initiation of warfarin, because of the shon half-life of 
the protein in vivo, whereas most of the procoagulant 
proteins have much longer half-lives. Fonunately, it seems 
that protein C is elaborated on a time-course similar to that 
of other \itamin-K-dependent factors. 
The occurrence of intraoperative thrombosis in this 
patient suggests that perioperative management of his 
protein C abnormality could have been improved upon, 
although thrombosis of the hepatic aneries and portal veins 
has also been seen in liver-transplant patients without 
protein C deficiency. Perhaps continued anticoagulation 
during the operative procedure will tum out to be the best 
course despite the added risks. Alternatively, higher doses of 
FFP before and during the operation might provide enough 
protein C to prevent thromboses. 
Severe homozygous protein C deficiency joins the 
growing list of metabolic disorders including alpha-l-
antitrypsin deficiency,18 Wilson's disease,'" hereditary 
tyrOsinaemia,lO type 1 and 4 glycogen storageJl.ll disease, 
Crigler-Najjar syndrome,ll' porphyri~I14 familial hyper-
cholesterolaemia,l5 factof VIII.16.l7 deficiency, and primary 
hyperoxalurialll that are correctable by hepatic 
transplantation. Yet, protein C deficiency is distinguished 
from all but the last three in that hepatic failure is not a 
primary feature of the disease. In fact, to our knowledge, 
protein C is the first coagulation defect in which liver 
transplantation has been done to correct the spt:cific 
disorder and not end-stage liver disease related to previous 
blood product therapy. Removal of the need for continuous 
warfarin therapy Of frequent infusions of plasma products 
has resulted in a sustained improvement in the quality of life 
for this child, despite the need for continuing 
immunosuppression. 
Further observation of this and other patients will be 
necessary before liver transplantation can be declared the 
treatment of choice for protein C defick'flCY. Future 
difficultic:i with this approach may be encountered. For 
example, protein C, like many other proteins, may exhibit 
polymorpbisms.4.l' ...... Therefore, protein C synthesised by 
donor liven may differ from that formerly synth\.."Sised by 
the recipient's liver. As a consequence, the patient'S immune 
system might respond by forming antibodies against the 
foreign protein C. In the future, other treatment methods 
will need to be pursued-in view of the inherent risks ofliver 
. transplamation and the fact that early morbidity such 
. IS blindness cartnOt conceivably be prev\"'fltcd by 
437 
transplantation. Ultimately, a genetic approach is likely to be 
most suCO!SSful, either through carrier dcttx:tion in high-risk 
populations or through gl.'fle therapy. 
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POSTOPERA T1VE POSITIVE NITROGEN 
BALANCE WITH INTRAVENOUS 
evmlkrqof1lM~ AND GROW1l1 HORMONE 
G. A. PONTING 
J. D. TF.ALEl 
D. HALUDI VI 
A.J. W. SIM 
Academic Surgical U.ar, St Mmy's 1I0 .• (>ital Medical School, 
London W2 I PG; ait~ of Cli,ricol Sciences, Clinical Re.!tarc1t 
Centre, Harrow;' and Dtpartmmr of Clinical Nutrition, St LuM.', 
IIM/'iral, GllildforcP 
Summary 11 parients having major gastrointestinal 
surgery were allocated at random to receive 
either biosynthetic human growth hormone (BSHGH) 0·1 
mg/kg or placebo daily for the first 7 postoperative days. All 
patients received the !:arne intravenoll!l feeding regimen, 
which mntaind 2·09 MJ glul..'OSC, 1·88 MJ fat, and 7 g N 
daily. Patients receiving BSHGH were in positive nitrogen 
balance throughout the study (mean 1'81 SEM 0·4) g NIday) 
and those receiving placebo were in negative nitrogen 
balance (mean -0,9 [0,7] g NIday). Resting energy 
expenditure progressively increased in the patients receiving 
BSHGH (115'7% (14'RJ on day 7) but remained unchanged 
in patients receiving placeho (99'35% [\'4)). Fat oxidation 
was nearly three times higher in the patients on BSHGH 
(4'09 [O'3RJ MJ/day) than in cuntrols (\'3R [0'50)). 
Carbohydrate oxidation remained ahout the same in both 
groups. Whole-body protein . turnover, synthesis, imd 
breakdown were increac;ed in the patients receiving growth 
hormone. 
Introduction 
AN inevitable accompaniment of the metabolic response 
to trauma is negative nitrogen balance. Although the 
administration of large quantities of intravenous nutrients 
(18 g Nand 12'55 MJ) (l MJ = 239 kcal) after operation can 
produce a positive nitrogen balance, I smaller quantities (10 g 
N and 2·09 Mj) only partly reverse the negative nitrogen 
balance.l Growth honnone improves nitrogen balance after 
thermal injury,16 major gastrointestinal surgery,' and in 
volunteers during intravenous nutrition." We have 
investigated the effect of hyponitrogenous hypocaloric 
intravenous nutrition and biosynthetic human growth 
hormone (BSHGH) on postoperative nitrogen, protein, and 
energy metabolism. 
Patients and Methods 
Patients having ma;or gastrointestinal tmet surgery wert 
alklC3led ~f random 10 receive either "SliGH ('Somatonorm', 
KabiVitrum) 0·1 mg/kg daily or placebo by intramu~cular injection 
for the the first 7 post~tive days. maticnl~ with diabetes, or who 
were on corticmte~I or who had evidence of sepsis or 
non-focalj~ed malignnnt disca,;e were excluded. 
A complete nutrient mixture ('Vitrimix', KabiVitnun) was 
infused rontinuously through an intravenous cannula inserted into 
a forearm vein. Tne CIIlOula was changed every 48 h or earlier if 
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TABLE I-DIAGNOSIS, AGE, AND BODY WEIGHT FOR TIll! PATII!NTS 
sruomo 
Age Initial wt 
-
(yr) Diagnosis (kg) 
Plactbo 
I 76 Anal carcinoma 456 
2 58 DiYttticular stricture 60·0 
:l 79 Dh-enicular di"""se 4B 
4 60 Gastric carcinoma 460{) 
5 73 Gastric ulcer and divertic;ular 
di...-e 630{) 
BSHUH 
6 71 Rectal carcinoma 750 
7 70 C'.attal carcinoma 84·0 
8 69 Oi\-enicular di"""oc 53'0 
9 70 Gastric carcinoma 65'0 
10 411 Otronic pancreatitis 62·0 
11 73 Rcmnncction of HIlfIInIInrII 61·0 
thrombophlebitis occurred. This regimen provided 7 g N, 2·09 MJ 
as carbohydrate, and 1·88 MJ as fat ('Intralipid', KabiVitrurn) 
daily. 
Venous blood samples were taken on the preoperative (tontrol) 
day and polltoperative days 1,3,5, and 7 and analysed for blood 
gluCO!le, plasma free fatty acids, senun insulin, and serum 
somatomedin-C. Free fatty acids, insulin, and somatomedin-C 
were measured by radioimmunoassay. 
Urine was collected throughout the study and nitrogen content 
measured I1y K;eldhal's t~hniqueK In calculating nitrogen balance 
we did not take acrount of either faecal or integumentary losses. 
Whole-body protein metabolism measurements were made on 
the 4th or 5th study days. Nitrogen turnover was calculated from 
the isotope enrichment in a sample of urine taken from the second 
12 h of a 24 h primed continuous intravenous infusion of 
t'N-labelled glycine.'o Protein synthesis and breakdown were 
derived by subtraction of nitrogen excretion and input, respectively, 
from turnover. Indirect calorimetry, with a rontinuous flow system, 
was done on the rontrol and 7 postoperative study days. The system 
has been validated by alcohol combustion and gas dilution." 
Resting energy expenditure and substrate oxidation rates were 
calculated as described by Frayn.12 
Results are expressed as mean and SEM. Statistical analysis was 
by the one-tailed Mann Whitney U test. The study was approved 
by the district ethics conuninee and informed consent was obtained 
from all patients. 
Results 
Of the 11 patients investigated 6 received BSHGH and 5 
placebo. Table I shows the details of the patients. The 
patients receiving growth hormone were significantly 
heavier (median weight 61·5 kg, range 53-84) than those 
receiving placebo (median 46, range 4O~P; p < 0'05). 
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